{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05835414",
            "orgStudyIdInfo": {
                "id": "BEP-001"
            },
            "organization": {
                "fullName": "BEP Medical Group, LLC",
                "class": "OTHER"
            },
            "briefTitle": "Electroencephalogram (EEG) Enhanced Transcranial Magnetic Stimulation (eTMS) for Chronic Trauma and Stressor-Related Disorders (TSRD)",
            "officialTitle": "Electroencephalogram (EEG) Enhanced Transcranial Magnetic Stimulation (eTMS) for Chronic Trauma and Stressor-Related Disorders (TSRD) (ETMS for Stress)",
            "acronym": "ETMS4Stress",
            "therapeuticArea": [
                "Other"
            ],
            "study": "electroencephalogram-eeg-enhanced-transcranial-magnetic-stimulation-etms-for-chronic-trauma-and-stressor-related-disorders-tsrd"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": true
            },
            "startDateStruct": {
                "date": "2023-04-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-18",
            "studyFirstSubmitQcDate": "2023-04-18",
            "studyFirstPostDateStruct": {
                "date": "2023-04-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-05-03",
            "lastUpdatePostDateStruct": {
                "date": "2023-05-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Marcia Bockbrader, MD PhD",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "BEP Medical Group, LLC"
            },
            "leadSponsor": {
                "name": "Marcia Bockbrader, MD PhD",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to learn about the safety, feasibility, and preliminary efficacy of EEG-enhanced transcranial magnetic stimulation (eTMS) as an adjunct to standard-of-care therapies for chronic trauma and stressor related disorders (TSRD) among US military veterans.\n\nThe main questions the study aims to answer are:\n\n* Is it safe to provide 30 sessions of eTMS for veterans with chronic TSRD?\n* Is it feasible to provide 30 sessions of eTMS as an adjunct to standard-of-care therapies for veterans with chronic TSRD?\n* Does health-related quality of life improve among veterans after 30 sessions of eTMS as an adjunct to standard-of-care therapies for chronic TSRD?\n\nParticipants will undergo 30 sessions of eTMS as an adjunct to standard-of-care therapies for veterans with chronic TSRD, weekly reassessment during treatment, and intermittent follow-up for 36 weeks post-enrollment."
        },
        "conditionsModule": {
            "conditions": [
                "Trauma and Stressor Related Disorders"
            ],
            "keywords": [
                "Transcranial Magnetic Stimulation",
                "Chronic Trauma and Stressor Related Disorders",
                "Veterans RAND 36-item health survey (VR-36)",
                "Health Related Quality of Life",
                "EEG",
                "Alpha Rhythms"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "This will be a staged, open-label, Phase II/III safety, feasibility, and efficacy investigational device trial. A staged approach will be utilized to assess safety, feasibility, and preliminary efficacy with 30 participants with an interim analysis after data collection at 6 weeks. If safety benchmarks are passed, the study will proceed with Stage 2, in which an additional 270 participants will be enrolled using randomization to multiple baselines for efficacy analyses.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Adjunctive eTMS treatment (no delay)",
                    "type": "EXPERIMENTAL",
                    "description": "6 weeks (30 sessions) of daily eTMS as an adjunct to standard of care TSRD treatment",
                    "interventionNames": [
                        "Device: Adjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Adjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS)",
                    "description": "Approximately 2000 pulses per session (x30 sessions) of midline prefrontal, repetitive transcranial magnetic stimulation at 50% or less of motor threshold, calibrated via EEG to a resonant alpha frequency of the participant, and given over approximately 12 minutes. Given as an adjunct to standard of care and integrative treatment for TSRD.",
                    "armGroupLabels": [
                        "Adjunctive eTMS treatment (no delay)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with device-related serious adverse events",
                    "description": "To address safety of the procedure, the study investigators will report number of participants (of 30 initial cohort) with expected, device-related serious adverse events (SAE's) or unexpected, device-related SAE's during treatment",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Rate of participants completing 80% of scheduled visits",
                    "description": "To assess feasibility of the procedure, the study investigators will report the rate of participants (for initial cohort of 30) completing \\>= 80% of the 30 scheduled eTMS sessions",
                    "timeFrame": "6 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Mean change in Veterans RAND 36-item health survey (VR-36) mental component scores (MCS)",
                    "description": "To assess efficacy of the procedure to improve health related quality of life, the study investigators will report the mean change from baseline to week 6 in mental component score (MCS) on Veterans RAND 36-item health survey (VR-36) for participants (in initial cohort of 30) who completed \\>=80% of eTMS sessions",
                    "timeFrame": "6 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Positive identification as a Veteran per discharge paperwork (DD-214, DD-215, NGB-22, NGB-22A) and photo ID, or Veterans Health Administration Veteran Health Identification Card (VHIC)\n* Presence of deployment-related stressful events (as defined by the Deployment Risk \\& Resilience Inventory-2, DRRI-2)\n* Trauma event(s) (defined on the Life Experiences Checklist for DSM-5, LEC-5)\n* Presence of 6 months or more of 6 or more \"moderate\" or worse symptoms from any of the five categories associated with stress disorders as operationalized on the PTSD Checklist for DSM-5 (PCL-5; intrusion, altered mood and cognitions, dissociation, avoidance, and arousal).\n* Informed consent for study participation, off label-eTMS, and data use\n* Enrollment in addiction services, if meets standard addiction treatment criteria\n* Enrollment in opioid reduction services, if dependent on opioids and morphine equivalent daily dose exceeds 50 mg (50 morphine equivalent daily dose, MEDD)\n* Agreement to limit daily alcoholic beverage consumption to no more than 2 servings\n* Signed pain contract, if MEDD \\>= 80, per State of Ohio prescribing guidelines\n\nExclusion Criteria:\n\n* Uncontrolled medical, psychological or neurological conditions including, but not limited to:\n* Uncontrolled psychosis or mania\n* Uncontrolled seizure disorder or EEG abnormalities that indicate risk of seizure, i.e., epileptiform discharges during the EEG recording\n* Uncontrolled cardiac, pulmonary, or endocrine disorder (e.g., diabetes)\n* Acute pain or illness\n* Active, untreated addiction to prescription drugs, alcohol or illicit substances (not including cannabis or derivatives, which are available in many states under medical prescription or for recreational use)\n* Clinically significant medical condition or abnormality that in the Investigator's judgment might pose a potential safety risk to the subject or limit the interpretation of the trial results\n* Pregnant, or female unwilling to use effective birth control during the course of the trial (unless cleared for participation by obstetrician/gynecologist)\n* Absolute contraindications to TMS: Presence of aneurysm clips or coils, cochlear or ocular implant, cortical epidural stimulator, deep brain stimulator, pacemaker or defibrillator, retained intracranial metal foreign body (bullets, shrapnel - excluding titanium and oral implants), steel stents or shunts, active vagal nerve stimulator, ventriculoperitoneal (VP) shunt.\n* Prior TMS treatment\n* Unwilling or unable to adhere to the study treatment, data collection schedule, or study procedures",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "22 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Marcia A Bockbrader, MD, PhD",
                    "role": "CONTACT",
                    "phone": "614-670-4000",
                    "email": "dr.marcie@bepmedicalgroup.com"
                },
                {
                    "name": "Neil B Austin",
                    "role": "CONTACT",
                    "phone": "614-670-4000",
                    "email": "neil@bepmedicalgroup.com"
                }
            ],
            "locations": [
                {
                    "facility": "BEP Medical Group LLC",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43221",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Practice Manager",
                            "role": "CONTACT",
                            "phone": "614-670-4000",
                            "email": "admin@bepmedicalgroup.com"
                        },
                        {
                            "name": "Marcia A Bockbrader, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "ICF",
                    "hasProtocol": false,
                    "hasSap": false,
                    "hasIcf": true,
                    "label": "Informed Consent Form",
                    "date": "2023-02-14",
                    "uploadDate": "2023-04-18T09:42",
                    "filename": "ICF_000.pdf",
                    "size": 244631
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014947",
                    "term": "Wounds and Injuries"
                },
                {
                    "id": "D000068099",
                    "term": "Trauma and Stressor Related Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17685",
                    "name": "Wounds and Injuries",
                    "asFound": "Trauma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M222",
                    "name": "Trauma and Stressor Related Disorders",
                    "asFound": "Trauma and Stressor Related Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T6034",
                    "name": "Quality of Life",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}